SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare’s US arm recalling 44,800 bottles of Paroxetine tablets

22 Sep 2017 Evaluate

Cadila Healthcare’s US arm -- Zydus Pharmaceuticals USA Inc -- is recalling 44,800 bottles of antidepressant Paroxetine tablets from the American market in the strength of 30 mg. The reason for the recall is the presence of foreign tablets. The voluntary ongoing nationwide recall is a class II recall.

According to the USFDA, a class II recall is initiated in a ‘situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote’.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

942.05 -0.50 (-0.05%)
20-Apr-2026 10:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1671.20
Dr. Reddys Lab 1235.00
Cipla 1237.85
Zydus Lifesciences 942.05
Lupin 2330.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×